Diakonos Oncology receives FDA fast track designation for pancreatic cancer dendritic cell vaccine

15 July 2024 - Diakonos Oncology announced today that the US FDA has granted fast track designation for the company’s unique ...

Read more →

US FDA approves Capvaxive (pneumococcal 21 valent conjugate vaccine) for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults

17 June 2024 - Capvaxive (V116) is specifically designed for adults and covers serotypes responsible for approximately 84% of invasive pneumococcal ...

Read more →

Bavarian Nordic completes BLA submission to US FDA for its Chikungunya vaccine candidate

17 June 2024 - First regulatory submission completed for CHIKV VLP seeking approval of the vaccine candidate for immunisation against chikungunya ...

Read more →

Novavax submits application to US FDA for updated protein based 2024-2025 formula COVID-19 vaccine

14 June 2024 - Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3. ...

Read more →

US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus vaccine for adults aged 50-59 at increased risk

7 June 2024 - Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of ...

Read more →

Moderna files FDA application for the JN.1 targeting COVID-19 vaccine

7 June 2024 - Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as ...

Read more →

Updated COVID-19 vaccines for use in the United States beginning in fall 2024

7 June 2024 - The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met on 5 June 2024 to ...

Read more →

Bavarian Nordic submits supplemental BLA seeking US FDA approval of freeze dried formulation of smallpox and mpox vaccine

31 May 2024 - Bavarian Nordic today announced the submission of a supplemental biologics license application to the US FDA ...

Read more →

Moderna receives US FDA approval for RSV vaccine mRESVIA

31 May 2024 - mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes ...

Read more →

Dynavax provides regulatory update on sBLA for four dose Heplisav-B regimen for adults on haemodialysis in the US

14 May 2024 - Dynavax Technologies today provided a regulatory update for the Company's supplemental biologics license application to include ...

Read more →

Moderna announces update on investigational RSV vaccine

10 May 2024 - US FDA has informed Moderna that due to administrative constraints, the agency will not complete its review ...

Read more →

Bavarian Nordic initiates rolling submission of biologics license application with FDA for its Chikungunya vaccine candidate

29 April 2024 - Bavarian Nordic today announced that it has initiated the rolling submission process with the US FDA ...

Read more →

GSK’s 5 in 1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA

16 April 2024 - Submission based on results from pivotal Phase III trial showing all primary outcomes met. ...

Read more →

ImmVira's oncolytic product MVR-T3011 IT intratumoral injection receives FDA fast track designation for HNSCC treatment

15 March 2024 - ImmVira has recently announced that the US FDA has granted fast track designation for oncolytic virus product ...

Read more →

CAN-3110 receives FDA fast track designation for treatment of recurrent high-grade glioma

13 February 2024 - Candel Therapeutics today announced that the US FDA granted fast track designation for CAN-3110 -- a first ...

Read more →